drugset
drugset / Trial / NCT06204250

A Study to Assess Safety and Tolerability of GS1-144 in Healthy Volunteers

NCT06204250 ↗

Phase 1 Completed 86 enrolled Changchun GeneScience Pharmaceutical Co., Ltd. Syneos Health · collab
RandomizedSequentialDouble-blindOther

Summary

The primary purpose of this study is to assess the safety and tolerability of single ascending doses of GS1-144 in healthy participants in Part 1 and to assess the safety and tolerability of multiple ascending doses of GS1-144 in healthy postmenopausal female participants in Part 2.

Timeline

Start
2024-02-27
Primary completion
2024-12-19
Completion
2024-12-19

Drugs

EvaluationDrugModalityDoseRoute
Subject GS1-144 Unknown 5 mg Oral
Subject GS1-144 Unknown 15 mg Oral
Subject GS1-144 Unknown 30 mg Oral
Subject GS1-144 Unknown 60 mg Oral
Subject GS1-144 Unknown 90 mg Oral
Subject GS1-144 Unknown 120 mg Oral

Indications

No indication recorded.